![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: C19orf12 |
Gene summary for C19ORF12 |
![]() |
Gene information | Species | Human | Gene symbol | C19orf12 | Gene ID | 83636 |
Gene name | chromosome 19 open reading frame 12 | |
Gene Alias | MPAN | |
Cytomap | 19q12 | |
Gene Type | protein-coding | GO ID | GO:0006873 | UniProtAcc | Q9NSK7 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
83636 | C19orf12 | HCC1_Meng | Human | Liver | HCC | 4.85e-63 | 6.08e-02 | 0.0246 |
83636 | C19orf12 | HCC2_Meng | Human | Liver | HCC | 5.45e-09 | 1.03e-02 | 0.0107 |
83636 | C19orf12 | HCC2 | Human | Liver | HCC | 3.45e-10 | 2.75e+00 | 0.5341 |
83636 | C19orf12 | S014 | Human | Liver | HCC | 2.67e-04 | 2.60e-01 | 0.2254 |
83636 | C19orf12 | S015 | Human | Liver | HCC | 1.70e-12 | 6.02e-01 | 0.2375 |
83636 | C19orf12 | S016 | Human | Liver | HCC | 1.10e-07 | 2.77e-01 | 0.2243 |
83636 | C19orf12 | S027 | Human | Liver | HCC | 3.06e-05 | 5.79e-01 | 0.2446 |
83636 | C19orf12 | S028 | Human | Liver | HCC | 2.53e-13 | 6.14e-01 | 0.2503 |
83636 | C19orf12 | S029 | Human | Liver | HCC | 1.76e-11 | 8.31e-01 | 0.2581 |
83636 | C19orf12 | C04 | Human | Oral cavity | OSCC | 2.15e-02 | 2.43e-01 | 0.2633 |
83636 | C19orf12 | C21 | Human | Oral cavity | OSCC | 1.48e-13 | 3.98e-01 | 0.2678 |
83636 | C19orf12 | C30 | Human | Oral cavity | OSCC | 8.41e-17 | 6.96e-01 | 0.3055 |
83636 | C19orf12 | C43 | Human | Oral cavity | OSCC | 1.21e-10 | 2.51e-01 | 0.1704 |
83636 | C19orf12 | C46 | Human | Oral cavity | OSCC | 1.27e-03 | 1.42e-01 | 0.1673 |
83636 | C19orf12 | C06 | Human | Oral cavity | OSCC | 1.20e-03 | 6.57e-01 | 0.2699 |
83636 | C19orf12 | C08 | Human | Oral cavity | OSCC | 2.06e-05 | 1.87e-01 | 0.1919 |
83636 | C19orf12 | SYSMH2 | Human | Oral cavity | OSCC | 1.43e-11 | 3.75e-01 | 0.2326 |
83636 | C19orf12 | SYSMH3 | Human | Oral cavity | OSCC | 2.35e-06 | 2.54e-01 | 0.2442 |
83636 | C19orf12 | SYSMH6 | Human | Oral cavity | OSCC | 4.73e-03 | 8.37e-02 | 0.1275 |
83636 | C19orf12 | male-WTA | Human | Thyroid | PTC | 7.81e-14 | 1.01e-01 | 0.1037 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006979111 | Esophagus | ESCC | response to oxidative stress | 303/8552 | 446/18723 | 7.15e-22 | 1.30e-19 | 303 |
GO:00069797 | Liver | NAFLD | response to oxidative stress | 78/1882 | 446/18723 | 7.85e-07 | 4.29e-05 | 78 |
GO:00515605 | Liver | NAFLD | mitochondrial calcium ion homeostasis | 8/1882 | 26/18723 | 3.06e-03 | 2.75e-02 | 8 |
GO:000697912 | Liver | Cirrhotic | response to oxidative stress | 196/4634 | 446/18723 | 2.80e-19 | 5.86e-17 | 196 |
GO:005156011 | Liver | Cirrhotic | mitochondrial calcium ion homeostasis | 15/4634 | 26/18723 | 3.43e-04 | 2.93e-03 | 15 |
GO:000697922 | Liver | HCC | response to oxidative stress | 281/7958 | 446/18723 | 9.75e-19 | 1.24e-16 | 281 |
GO:005156021 | Liver | HCC | mitochondrial calcium ion homeostasis | 20/7958 | 26/18723 | 3.82e-04 | 2.61e-03 | 20 |
GO:000697920 | Oral cavity | OSCC | response to oxidative stress | 273/7305 | 446/18723 | 8.35e-22 | 1.65e-19 | 273 |
GO:00515607 | Oral cavity | OSCC | mitochondrial calcium ion homeostasis | 18/7305 | 26/18723 | 1.75e-03 | 8.28e-03 | 18 |
GO:0006979113 | Thyroid | PTC | response to oxidative stress | 234/5968 | 446/18723 | 6.97e-20 | 9.77e-18 | 234 |
GO:00515608 | Thyroid | PTC | mitochondrial calcium ion homeostasis | 19/5968 | 26/18723 | 1.93e-05 | 1.98e-04 | 19 |
GO:000697934 | Thyroid | ATC | response to oxidative stress | 246/6293 | 446/18723 | 2.98e-21 | 6.09e-19 | 246 |
GO:005156014 | Thyroid | ATC | mitochondrial calcium ion homeostasis | 19/6293 | 26/18723 | 4.49e-05 | 3.61e-04 | 19 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C19orf12 | SNV | Missense_Mutation | rs397514477 | c.32N>T | p.Thr11Met | p.T11M | Q9NSK7 | protein_coding | tolerated(0.08) | benign(0.01) | TCGA-AO-A03V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | SD |
C19orf12 | insertion | Frame_Shift_Ins | novel | c.199_200insGG | p.Ala67GlyfsTer7 | p.A67Gfs*7 | Q9NSK7 | protein_coding | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD | ||
C19orf12 | SNV | Missense_Mutation | rs139422624 | c.376G>A | p.Glu126Lys | p.E126K | Q9NSK7 | protein_coding | tolerated(0.6) | benign(0.018) | TCGA-AA-A00N-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
C19orf12 | SNV | Missense_Mutation | novel | c.100G>A | p.Ala34Thr | p.A34T | Q9NSK7 | protein_coding | tolerated(0.07) | possibly_damaging(0.481) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR |
C19orf12 | insertion | Frame_Shift_Ins | rs749721914 | c.199_200insG | p.Ala67GlyfsTer16 | p.A67Gfs*16 | Q9NSK7 | protein_coding | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
C19orf12 | deletion | Frame_Shift_Del | c.199delN | p.Ala67LeufsTer6 | p.A67Lfs*6 | Q9NSK7 | protein_coding | TCGA-G4-6320-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | oxaliplatin | SD | |||
C19orf12 | SNV | Missense_Mutation | rs544395324 | c.101C>T | p.Ala34Val | p.A34V | Q9NSK7 | protein_coding | tolerated(0.39) | benign(0.369) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
C19orf12 | SNV | Missense_Mutation | novel | c.401C>T | p.Ala134Val | p.A134V | Q9NSK7 | protein_coding | tolerated(0.08) | benign(0.097) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
C19orf12 | SNV | Missense_Mutation | c.301A>G | p.Asn101Asp | p.N101D | Q9NSK7 | protein_coding | tolerated(0.56) | benign(0) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
C19orf12 | SNV | Missense_Mutation | novel | c.374N>A | p.Ser125Asn | p.S125N | Q9NSK7 | protein_coding | tolerated(1) | benign(0.012) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |